P1.14-58 A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer

Julia Rotow, C. Blakely, Caroline E. McCoach et al.|Journal of Thoracic Oncology|2019

Cited by 8